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ABSTRACT 
 
Objectives: Patients with difficult-to-treat rheumatoid arthritis (RA) remain symptomatic despite 
treatment according to current EULAR management recommendations. These focus on early 
phases of the disease and pharmacological management. We aimed to identify characteristics 
of difficult-to-treat RA and issues to be addressed in its workup and management that are not 
covered by current management recommendations. 
 
Methods: An international survey was conducted among rheumatologists with multiple-choice 
questions on disease characteristics of difficult-to-treat RA. Using open questions, additional 
items to be addressed and items missing in current management recommendations were 
identified. 
 
Results: 410 respondents completed the survey: 50% selected disease activity score assessing 
28 joints (DAS28) >3.2 OR presence of signs suggestive of active disease as characteristics of 
difficult-to-treat RA; 42% selected fatigue; 48% selected failure to ≥2 conventional synthetic 
disease-modifying anti-rheumatic drugs (DMARDs) AND ≥2 biological/targeted synthetic 
DMARDs; 89% selected inability to taper glucocorticoids below 5 or 10 mg prednisone 
equivalent daily. Interfering comorbidities, extra-articular manifestations and polypharmacy were 
identified as important issues missing in current management recommendations. 
 
Conclusions: There is wide variation in concepts of difficult-to-treat RA. Several important issues 
regarding these patients are not addressed by current EULAR recommendations. 
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INTRODUCTION 
 
The European League Against Rheumatism (EULAR) recommendations and the American 
College of Rheumatology (ACR) guidelines on management of rheumatoid arthritis (RA) focus 
on early phases of the disease and on pharmacological management.[1,2] These 
recommendations suggest intensifying the disease-modifying anti-rheumatic drug (DMARD) 
strategy, if improvement or the treatment target is not achieved within 3 or 6 months, 
respectively. Nevertheless, a significant proportion of patients remains symptomatic after 
several cycles of treatment, which makes them difficult-to-treat; this is a significant clinical 
problem in daily practice.[3]  
A wide array of potential factors contributes to difficult-to-treat RA, such as DMARD resistance 
or intolerance, adverse reactions, treatment non-adherence and limited drug options due to 
comorbidities. Importantly, RA patients may also remain symptomatic due to non-inflammatory 
factors, such as secondary osteoarthritis, pain syndromes, social and occupational decline and 
coping difficulties. All these may (in different combinations) play a role in individual patients and 
require specific management approaches, which should be addressed in management 
recommendations. 
Currently, different concepts exist on difficult-to-treat RA, such as refractory, multidrug resistant 
or persistent RA, or concepts based on number of failed DMARDs and failed treatment 
goals.[4–7] Depending on the criteria used, the estimated prevalence of difficult-to-treat RA 
ranges from 5 to 20%.[6]  
We aimed to identify characteristics of the concept of difficult-to-treat RA and to explore issues 
to be addressed in its workup and management that are not covered by current EULAR 
management recommendations. 
 
METHODS 
 
Online survey among rheumatologists 
An online survey (Supplementary File 1, set up by DvdH, GN, JWGJ, JMvL, MJHdH and PMJW) 
was conducted among rheumatologists (including rheumatologists-in-training). The survey was 
distributed by email in the network of the authors and by Emerging EULAR Network 
(EMEUNET), and it was asked to additionally forward it to other rheumatologists. The survey 
consisted of two questions regarding the background of the respondents (Where do you work? 
How many RA patients do you treat?).  
  
 
Four multiple-choice questions addressed the necessity of incorporating the following items, and 
their cut-offs, into the concept of difficult-to-treat RA: disease activity level; presence of fatigue; 
number of DMARDs that failed; inability to taper glucocorticoid (GC) treatment. Only one 
response option could be selected at each multiple-choice item, which were selected as -
according to expert opinion - among the most frequent and relevant characteristics in clinical 
practice. Fatigue was selected as one of the most relevant patient reported outcomes in RA.[8]  
Three open questions were: ‘Please define any additional characteristics and suggested criteria 
for difficult-to-treat RA’; ‘Please mention additional clinical issues or comorbidities to be 
addressed in the workup and management of these patients’; ‘Please mention any clinically 
relevant situations which are not covered by the current RA EULAR recommendations’. 
 
Qualification and quantification of the responses to the open questions 
NMTR and MJHdH independently classified the responses to the open questions into categories 
(Supplementary File 1). This enabled summarising and quantifying. Categories were defined 
based on the responses that were given to the open questions. One response could fit multiple 
categories. ‘Other’ was used to classify characteristics that did not fit into one of the categories. 
Discrepancies in classification between NMTR and MJHdH were resolved by consensus. 
 
Statistical analyses 
All responses were evaluated using descriptive statistics, performed using IBM SPSS Statistics 
21 software. 
 
RESULTS  
 
Respondents 
410 respondents from 33 countries completed the survey between July 2017 and March 2018. 
Of the 385 respondents who filled out the name of their country, 96% was European (Figure 1); 
25% of respondents treated <100 unique patients with RA, 42% 100-300 patients, and 32% 
>300 patients (n=7 missing). 
 
  
  
 
Figure 1. Number of respondents per country 
 
Selected difficult-to-treat RA disease characteristics 
50% of respondents selected ‘DAS28-ESR>3.2 OR presence of signs suggestive of active 
inflammatory disease activity with a DAS28-ESR≤3.2’ as characteristics (Figure 2a). 42% 
included fatigue (Figure 2b). 48% selected ‘≥2 conventional synthetic (cs)DMARDs AND ≥2 
biological (b)DMARDs or targeted synthetic (ts)DMARDs with different mode of action’ for how 
many insufficiently effective anti-rheumatic drugs should at least have been applied (Figure 2c). 
89% selected inability to taper GCs <5 (43%) or 10 (46%) mg prednisone or equivalent daily for 
more than 1 year, irrespective of DMARD treatment (Figure 2d), as difficult-to-treat RA 
characteristic.  
 
Additional difficult-to-treat RA characteristics  
243 additional characteristics for difficult-to-treat RA were given by 169 respondents (Figure 2e), 
most frequently categorised into ’interfering comorbidities’ and ‘extra-articular manifestations’. 
Examples are cardiovascular risk, malignancies, interstitial lung disease and vasculitis. A 
diversity of ‘other’ responses was given, e.g. inflammation on magnetic resonance imaging, 
morning stiffness and patient dissatisfaction. 
 
Less than 4: Austria, Belarus, Bulgaria, Denmark, Egypt, Estonia, Iceland, Israel, Kenya, Pakistan, Russia, Serbia, 
Slovakia, Slovenia, Tunisia, Turkey 
  
 
Figure 2. Difficult-to-treat RA characteristics 
b/tsDMARDs: biological/targeted synthetic disease-modifying anti-rheumatic drugs; csDMARDs: conventional synthetic disease-
modifying anti-rheumatic drugs; DAS28-ESR: disease activity score assessing 28 joints using erythrocyte sedimentation rate; RA: 
rheumatoid arthritis; US: ultrasonography. 
* with different mode of action 
° or equivalent daily for more than 1 year, irrespective of DMARD treatment 
  
 
 
Interfering clinical issues and items missing in current EULAR recommendations, 
important to manage difficult-to-treat RA 
For interfering issues to be addressed in the workup and management of difficult-to-treat RA, 
396 suggestions were given by 170 respondents (Figure 3a), most frequently cardiovascular 
disease and extra-articular manifestations. Other interfering clinical issues were drug 
intolerance, smoking and chronic liver disease. 
For issues not covered by the current EULAR recommendations, 64 were mentioned by 54 
respondents  (Figure 3b). These were most frequently classified as interfering comorbidities and 
extra-articular manifestations. Also issues regarding pharmacological management (e.g. 
tapering regimen, adverse events and polypharmacy), pain syndromes and pregnancy and 
lactation were mentioned. Other items were ongoing joint destruction, coping problems and 
persistent single joint involvement. 
  
 
  
  
 
EULAR: European League Against Rheumatism; RA: rheumatoid arthritis.  
* e.g. tapering strategies, adverse events, polypharmacy 
Figure 3. Interfering clinical issues and items missing in the current EULAR recommendations, 
important to manage difficult-to-treat RA  
 
DISCUSSION 
 
Our results show a wide variety in concepts of difficult-to-treat RA; active disease, failure to 
DMARDs treatment and inability to taper GCs are considered main characteristics. Additional 
difficult-to-treat RA characteristics were mostly related to extra-articular manifestations and 
interfering comorbidities that may hamper assessment of disease activity or limit treatment 
possibilities. As items missing in current RA EULAR management recommendations, interfering 
comorbidities (especially cardiovascular disease, infection and malignancy), extra-articular 
  
 
manifestations, pharmacological management (e.g. tapering strategies, adverse events and 
polypharmacy) and pain syndromes were mentioned most frequently. 
Of the factors mentioned as contributing to difficult-to-treat RA in this survey, e.g. treatment non-
adherence, adverse events and coping strategies, exact prevalences are unknown. These 
should be determined in future research for an indication of their need to be included in 
management recommendations. 
Our results mainly reflect how difficult-to-treat RA is experienced in European countries. 
Additional contributing factors to difficult-to-treat RA in countries outside Europe might be limited 
access to diagnostic tests, rheumatologists and DMARDs. These should be addressed in 
management recommendations as well. 
Our study has limitations. The survey was distributed via email and it was asked to forward it to 
other rheumatologists to increase the number of respondents. As a drawback, the total number 
of rheumatologists who received it is unknown.  
The four multiple-choice questions had pre-specified response options, limiting input to these 
questions, but enabling the responses to be easily summarised and quantified. The open 
questions required a classification system for the responses; some responses were classified in 
two categories and there was a number of responses that was classified as ‘other’. Additionally, 
the pre-specified multiple-choice questions may have biased the results of the open questions. 
However, by these open questions, we received a large inventory of issues that may need to be 
addressed in clinical practice. 
The strengths of this study are the large number of respondents and of European countries 
represented by the respondents; the many suggestions of items which are not covered by the 
current EULAR RA management recommendations underline the unmet clinical need for this 
subpopulation of RA patients.  
Recently a EULAR Task Force has been initiated on the development of recommendations for 
the comprehensive management of difficult-to-treat RA. The results of this survey will fuel 
discussions on items to include in the management recommendations of difficult-to-treat RA. 
In conclusion, the results of this survey underscore the difficulty in establishing an unambiguous 
concept of difficult-to-treat RA, which is seen as a heterogeneous condition not fully covered by 
current EULAR recommendations. The recently established EULAR Task Force will explore the 
management of difficult-to-treat RA further. 
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SUPPLEMENTARY FILE 1 
 
Questionnaire 
 
Q1: Where do you work? (city, country) 
_____________________________ 
 
Q2: How many RA patients do you treat? 
a. Less than 100 
b. Between 100 and 300 
c. More than 300 
d. I’m not a physician 
 
Q3: What should be the definition for not well-controlled disease in the definition of difficult-to-
treat RA? 
a. DAS28-ESR > 3.2 
b. DAS28-ESR > 5.1 
c. DAS28-ESR > 3.2 OR presence of signs suggestive of active inflammatory disease activity 
with a DAS28-ESR ≤ 3.2 
d. DAS28-ESR > 5.1 OR presence of signs suggestive of active inflammatory disease activity 
with a DAS28-ESR ≤ 5.1 
e. Other (please specify) _____________________________ 
 
Q4: Would you include fatigue in the definition of not well-controlled disease? 
a. Yes 
b. No 
c. Please elaborate (if applicable) _____________________________ 
d. Other (please specify) _____________________________ 
 
Q5: Which and how many anti-rheumatic drugs should at least be tried with insufficient effect 
(failed) for the definition of difficult-to-treat RA: 
a. ≥1 csDMARD AND ≥2 b/tsDMARDs with different mode of action 
b. ≥2 csDMARDs AND ≥2 b/tsDMARDs with different mode of action 
c. ≥2 csDMARDs AND ≥3 b/tsDMARDs with different mode of action 
  
 
d. ≥2 csDMARDs AND ≥4 b/tsDMARDs with different mode of action 
e. Further suggestions (please specify) _____________________________ 
 
Q6: Treatment with glucocorticoids should be mentioned in the criteria for difficult-to-treat RA as 
follows: 
a. Unable to taper glucocorticoids below 5 mg prednisone or equivalent daily for more than 1 
year, irrespective of DMARD treatment 
b. Unable to taper glucocorticoids below 10 mg prednisone or equivalent daily for more than 1 
year, irrespective of DMARD treatment 
c. Glucocorticoids should not be included in the criteria 
d. Suggested glucocorticoid dose/duration of treatment (if other than above) _______________ 
 
Q7: Please define any additional characteristics and suggested criteria for difficult-to-treat RA 
_____________________________ 
 
Q8: Please mention additional clinical issues or comorbidities to be addressed in the workup 
and management of these patients 
_____________________________ 
 
Q9: Please mention any clinically relevant situations which are not covered by the current RA 
EULAR recommendations 
_____________________________ 
 
 
Categories per question 
 
We have created this categories to categorise the responses to the open questions. If not 
clearly stated if a disease/problem was meant as ‘extra-articular manifestation’ or as ‘interfering 
comorbidity’ it was classified according to both categories 
 
Q7: Please define any additional characteristics and suggested criteria for difficult-to-treat RA 
● Interfering comorbidities 
● Extra-articular manifestations 
● Radiographic progression 
  
 
● Persistence of US synovitis 
● Side effects 
● Treatment non-adherence 
● Already included in former questions 
● Arthritis of the feet 
● Treatment delay 
● Non-inflammatory complaints 
● Other 
 
Q8: Please mention additional clinical issues or comorbidities to be addressed in the workup 
and management of these patients 
● Cardiovascular disease 
● Extra-articular manifestations 
● Infection 
● Malignancy 
● Diabetes Mellitus 
● Osteoporosis 
● Pain syndrome 
● Lung disease 
● Kidney disease 
● Depression 
● Obesity 
● Gastrointestinal disease 
● Osteoarthritis 
● Other 
 
Q9: Please mention any clinically relevant situations which are not covered by the current RA 
EULAR recommendations 
● Interfering comorbidities 
● Extra-articular manifestations 
● Pharmacological management 
● Pain syndrome 
● Pregnancy/lactation 
● Other 
